NCT07500376 Multimodal Nutritional and Sarcopenia Assessment for Risk Stratification in Lung Cancer Surgery
| NCT ID | NCT07500376 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ondokuz Mayıs University |
| Condition | Lung Cancer (Non-Small Cell) |
| Study Type | OBSERVATIONAL |
| Enrollment | 142 participants |
| Start Date | 2026-03-15 |
| Primary Completion | 2026-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 142 participants in total. It began in 2026-03-15 with a primary completion date of 2026-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective observational cohort study aims to evaluate the prognostic value of multimodal nutritional status and sarcopenia assessment in patients undergoing lung cancer surgery. Postoperative complications, mortality, and prolonged hospital stay remain major clinical concerns in thoracic surgery. Although malnutrition and sarcopenia are recognized as important determinants of surgical outcomes, their combined and multidimensional evaluation has not been sufficiently studied. Adult patients undergoing anatomical lung resection for primary lung cancer will be included. Nutritional status will be assessed using serum biomarkers, inflammatory indices, and validated clinical nutritional scores. Sarcopenia will be evaluated using computed tomography-based muscle mass and density measurements, as well as ultrasonographic muscle thickness. These parameters will be analyzed in relation to postoperative complications, intensive care unit (ICU) requirement, length of hospital stay, and mortality. Multivariable analyses will be performed to identify independent predictors, and a combined risk stratification model will be developed. This study aims to improve preoperative risk assessment and to support personalized perioperative management strategies, including identification of patients who may benefit from targeted nutritional optimization and prehabilitation.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Patients undergoing anatomical lung resection (lobectomy or segmentectomy) for primary lung cancer * Availability of preoperative thoracic computed tomography (CT) within 30 days before surgery * Completion of preoperative nutritional assessment and ultrasonographic muscle measurements * Ability to provide written informed consent Exclusion Criteria: * Receipt of neoadjuvant chemotherapy, immunotherapy, or radiotherapy * Emergency surgery * Pneumonectomy * Combined resection of another organ during the same procedure * Inadequate or non-evaluable imaging or measurement data * Immunosuppressive therapy or presence of advanced/metastatic disease * Significant thoracic deformity or prior conditions interfering with muscle measurements * Refusal or inability to provide informed consent
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07500376 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer (Non-Small Cell). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07500376 currently recruiting?
Yes, NCT07500376 is actively recruiting participants. Contact the research team at drcanerisevi@gmail.com for enrollment information.
Where is the NCT07500376 trial being conducted?
This trial is being conducted at Samsun, Turkey (Türkiye).
Who is sponsoring the NCT07500376 clinical trial?
NCT07500376 is sponsored by Ondokuz Mayıs University. The trial plans to enroll 142 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.